^
    Back
    Association details:
    Biomarker:RET C634W
    Cancer:Thyroid Gland Carcinoma
    Drug:Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Int J Cancer
    Title:

    Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

    Excerpt:
    Regorafenib also demonstrated potent inhibition (20–40 nM) of the oncogenic RTKs KITK642E and RETC634Win vitro (Table 1), which indicates that regorafenib may have clinical potential in tumor types driven by mutated RET, which occurs in a subset of medullary thyroid tumors, or mutated KIT in GIST.
    DOI:
    10.1002/ijc.25864